BioSpace News Archive

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will host its 2023 Investor Day on Wednesday, May 24, starting at 9:00 a.m. (ET)in New York City.

Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA ® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED).

Asieris Pharmaceuticals announced that its subsidiary, Hainan Yahong pharmaceutical Trading Co., Ltd., was issued the Drug Distribution License by the Hainan Provincial Drug Administration.

PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately.

Hillstream BioPharma, Inc. announced pharmacokinetic (PK) data of HSB-1216 supportive of its development strategy and pre-clinical data.

MedGenome, a global precision medicine company specializing in omics solutions, today announced that it will be exhibiting at the American Association for Cancer Research Annual Meeting on April 14 – 19, 2023 in Orlando, Florida.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), today announced that it will report its First Quarter 2023 results on Wednesday, April 26, 2023 after the Mexican Market (BMV) close.

Reach Neuro, Inc., a neurotechnology company giving control and independence back to people with debilitating neurological disorders, announced today that it has been granted a Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Avantis platform.